Enterprise Value
-89.69M
Cash
280.8M
Avg Qtr Burn
-16.16M
Short % of Float
10.70%
Insider Ownership
7.05%
Institutional Own.
88.18%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
NKX019 (CAR NK cell therapy) Details B-cell malignancies, Non-Hodgkin lymphoma, B-cell lymphoma | Phase 1 Data readout | |
NKX101 (CAR-T targeting NKG2D) Details Bone marrow disorder, Acute myeloid leukemia, Cancer, Myelodysplastic syndrome | Phase 1 Data readout | |
NKX019 (CAR NK cell therapy) Details Lupus nephritis, Autoimmune disease | Phase 1 Initiation |